Bristol Myers brings IRA drug pricing fight to Supreme Courtnews2025-12-22T18:04:49+00:00December 22nd, 2025|Endpoints News|
US charges six people with insider trading in case including Olema Oncologynews2025-12-22T17:43:48+00:00December 22nd, 2025|Endpoints News|
Windward gets bispecific from Qyuns in its second China deal of the yearnews2025-12-22T15:46:03+00:00December 22nd, 2025|Endpoints News|
Shionogi to pay $2.5B to acquire one of the only approved ALS drugsnews2025-12-22T15:45:39+00:00December 22nd, 2025|Endpoints News|
Ipsen gains access to ADC from Shanghai biotech Simcere Zaimingnews2025-12-22T14:12:36+00:00December 22nd, 2025|Endpoints News|
Boehringer taps Rectify to create pills for chronic kidney diseasenews2025-12-22T13:00:04+00:00December 22nd, 2025|Endpoints News|
AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancernews2025-12-22T12:09:55+00:00December 22nd, 2025|Endpoints News|
Aktis Oncology files for IPO to fund Lilly-partnered radiopharma pipelinenews2025-12-22T10:45:45+00:00December 22nd, 2025|Endpoints News|
Nine more MFN deals; Western drugmakers turn to China; Chai Discovery’s raise; and morenews2025-12-20T11:00:59+00:00December 20th, 2025|Endpoints News|
FDA approves Cytokinetics’ heart drug, giving it an edge over BMS rivalnews2025-12-19T22:01:44+00:00December 19th, 2025|Endpoints News|
